AzTrials
AzTrials

Fever of Unknown OriginFUONCT04810351

Fever of Unknown Origin (FUO) in Elderly Patients

An observational study of Fever of Unknown Origin, run by Universitair Ziekenhuis Brussel at 1 site in Belgium.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Objective: Fever of unknown (FUO) origin remains challenging in geriatric patients. Geriatric patients have a blunted immune response responsible for altered fever mechanisms and immune cells responses. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Fever of Unknown Origin
What is being tested?
observational study
Type of treatment
Pill or oral medicine
How many people
0 participants
Where
1 siteBelgium
Study dates
1 Oct 2021to 31 Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients will be recruited at the geriatric unit and internal medicine unit or geriatric outpatient clinic of UZ Brussel and will be followed during one year. Cfr inclusion and exclusion criteria

Who may be able to join

  • fever during more than one week out of hospital or more than 3 weeks with an intelligent appropriate workup
  • an inflammatory syndrome during more than one week out of hospital or more than 3 weeks out of hospital
  • The exclusion criteria :
  • no inform consent
  • Age < 18 years old
  • Neutropenia, HIV or nosocomial fever of unknown origins are excluded. Immunodepressed patients are also excluded.

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • UZ brussel

    Brussels, Jette, 1090

Other trials in Belgium

About this study

Objective: Fever of unknown (FUO) origin remains challenging in geriatric patients. Geriatric patients have a blunted immune response responsible for altered fever mechanisms and immune cells responses. Consequently, FUO could be inappropriately named and could be changed in Inflammation of unknown origin (IUO) in this specific population. Furthermore, the studies of FUO in this group are (out)dated and the diagnostic methods have evolved achieving a better sensitivity and specificity. The aim of our study is to assess the spectrum of diseases responsible of FUO or IUO in elderly patients compared to younger patients and to define the diagnostic approach using new diagnostic investigations. The second aim of our study is to assess the usefulness of inflammatory markers, demographic data and comorbidity to differentiate the cause of FUO/IUO.

Design: Patients with FUO or IUO will prospectively be recruited at the geriatric unit and the internal medicine unit of the UZ hospital during four years. The demographic, social and medical data will be screened. All diagnostic methods will be described.

Read the detailed description

Until today, diagnose of fever of unknown origin remains challenging in elderly patients. The presentation of the disease is often atypical and this can delay diagnose and treatment. Geriatric patients have a blunted immune response responsible for altered fever mechanisms. For example, thirty-two percent of geriatric patients presented an infection at the emergency service having no pyrexia or increased white blood cell count in the presence of an infection.

Consequently, the definition of FUO in older patients is different from younger patients. FUO in older patients is defined as tympanic or axillar fever > 37.2.0C, a rectal fever more than 37.50C or a change of > 1.3 centigrade from basal temperature during more than 3 weeks. Furthermore, the name FUO is probably not appropriate in this population and should be replaced with inflammation of unknown origin. However, Unger et al also proposed inflammation of unknown origin in a younger population.

Knockaert et al have shown that the causes of FUO are different in older patients compared to young patients. The causes of FUO are more frequently found in older patients (> 65 years old) compared to younger patients (87-95% and 79% respectively). One explanation is the atypical presentation of classic diseases in geriatric patients. Infection, multi-system diseases and neoplasms were the most prevalent causes. These studies are old and the sensitivity and specificity of the diagnostic methods used presently, such as FDG-Pet-CT, have changed. The spectrum of diseases responsible of FUO or IUO in older patients could therefore have changed since the Knockaert studies. These new diagnostic methods allow better diagnose but also faster diagnose. Consequently the definition of FUO can become obsolete in the field of the duration of the fever.

Materials and Methods

The design of the study is an observational prospective study which will start in juli 2021 until open date in function of the number of included patient (at least 50 patients in both groups).

Patients will be recruited at the geriatric unit and internal medicine unit or geriatric outpatient clinic or internal medicine outpatient clinic of UZ Brussel and will be followed during one year.

The outpatient clinic patients will be recruited during the consultation; the patients who are hospitalized will be recruited during the first week of hospitalization.

The exclusion criteria are the impossibility to have an informed consent from the patient of a representative of the patient. Neutropenia, HIV or nosocomial fever of unknown origins are excluded. Immunodepressed patients are also excluded.

Patients:

All subjects will be screened for underlying illnesses by direct questioning, medical archives and blood sampling. Social evaluation will include determination of age, gender, home (private versus institution), and marital status. Clinical data will comprise: smoking and alcohol habits, old work, hobbies, travel, animal's owner, pneumococcal and influenza vaccine status, allergy, Body mass index (BMI), medical history, current treatment and reasons for hospitalization, recent antibiotic or corticoid treatment. For the older patients (> 70 years old) we will perform a CGA to identify comorbidity and common geriatric conditions. The polypathology and the severity of the medical problems will be scored using the "Charlson comorbidity Index"15 and "Cumulative Illness Rating Scale-Geriatric" (CIRS-G). It is an instrument to quantify disease burden. It comprises a comprehensive review of medical problems of 14 organ systems. It is based on a 0 to 4 rating of each organ system. The "Geriatric Depression Scale" will be used to assess the probability of depressed mood (GDS-15) in 15 questions. The assessment of "Activities of Daily Living" (ADL) will be made by using Katz's scale. It includes the following items: bathing, dressing, transfer, toilet, continence and eating. Each task is graded on a 3-level scale (1 to 3 for Katz's scale), where lower levels represent the absence of dependence and upper level the maximal dependence for the task. Cognitive functions will be assessed using the "Mini Mental State Examination" (MMSE). Possible scores range from 0 to 30 points, with lower scores indicating impaired cognitive function. Nutritional status was assessed using the "Mini Nutritional Assessment" (MNA). A score ≥ 24 identifies patients with a good nutritional status. Scores between 17 and 23.5 identify patients at risk of malnutrition. These latter patients have not yet started to lose weight and do not show low plasma albumin levels but have lower protein-caloric intakes than recommended. A score < 17 indicates protein-caloric malnutrition. Pain will be assess using a visual analogical scale from 0 to 10 points.

Methods

All diagnostic method means from the standard care of the patients during the hospital stay performed for the assessment of the fever or inflammatory syndrome will be collected:

  • biological analyses, (such as CRP, renal function, lever function, electrolytes, sedimentation rates, uric acid, TSH, vitamin B12, folic acid, 25(OH) vitamin D, hemoglobin, hematocrit, proteins, albumin, white blood cells and formula, creatinine clearance (Cockcroft and de Gault formula), autoimmune assessment, viral or bacterial serology,…
  • urine analyses
  • Bacterial culture or PCR, viral PCR test in body fluids.
  • Pleural puncture
  • Lumbar puncture
  • body sonography
  • body X-rays and tomography
  • Pet Ct
  • Temporal artery biopsy
  • Tissue biopsy
  • Bronchoscopy
  • Laparoscopy
  • Bone marrow aspirate
  • ….

Statistics:

Description statistics will be used such as means, medians, standard deviation and interquartile ranges.

Confidentiality All data will be collected by the investigators. The data will be collected in a way that patient names will not appear in the database (Redcap) and that individual patients will not be recognized by the examination of the collected data. Each patients will receive a code to preserve the anonymization. This code is a nummer that will be record on a listing of patients participating to the study in KWS. The listing in KWS is recorded in the worklisting CGER and is named FUO. Each investigator will be responsible of the anonymization of his/her recruiting. The database will only be accessible by the investigators and protected in Redcap by a password. The database (Excel) will be saved on UZBrussel server (CGER) in a folder named FUO.

Being tested
observational study
Keywords
FUO, Fever of unknown origin
Medical subject headings
Fever of Unknown Origin

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • observational studyOther

    There is no intervention. It is an observational study

Study groups in NCT04810351
Study groupRoleWhat they receive
Younger 1young patients ( 18-69 years old) with oral or rectal fever > 37°8 or tympanic fever > 37°2 or CRP > 30 mg/dl during more than one week but less than three weeks of hospital with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever
Receives: Other: observational study
Older 1old patients ( > 70 years old) with oral or rectal fever > 37°8 or tympanic fever > 37°2 or CRP > 30 mg/dl during more than one week but less than three weeks out of hospital with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever
Receives: Other: observational study
Young 2young patients (18-69 years old) with oral or rectal fever > 37°8 or tympanic fever > 37°2 or CRP > 30 mg/dl during more than 3 weeks with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever.
Receives: Other: observational study
Older 2old patients ( > 70 years old) with oral or rectal fever fever > 37°8 or tympanic fever > 37°2 or CRP > 30 mg/dl during 3 weeks with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever13 .
Receives: Other: observational study

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. the spectrum of diseases responsible of FUO or IUO

    The proportion of infectious diseases, of neoplasm, of multi system disease of pulmonary embolism or deep vein thrombosis, of intoxication door medication will be measured in both groups

    Measured: through study completion, an average of 1 year

  2. definition of FUO

    we would like to compare fever of unknown origin since three weeks with fever of unknown origin since one week

    Measured: through study completion, an average of 1 year

  3. Diagnostic approach of FUO

    To describe the diagnostic approach and compare these diagnostic test in young and old population.

    Measured: through study completion, an average of 1 year

Secondary outcomes (1)
  1. Factors which influence FUO

    Univariate and multivariate analyses will be used to measure the influence of age (years), gender, marital status, current treatment, comorbidities, recent use of antibiotics or corticoïd, Comprehensive geriatric assesment (MMSE, MNA, Katz, Lawton, CIRS-G, Charlson Index, GDS) on the cause of fever of unknown origin in both groups.

    Measured: At baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Mar 2021
  2. Study start1 Oct 2021
  3. Primary completion31 Dec 2023
  4. Study completion31 Dec 2023

Why it stopped: Not working anymore at this hospital

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04810351
Sponsor's protocol ID
UZCompte2
Acronym
FUO
Status last verified
Apr 2026
First submitted
11 Mar 2021
Last updated
4 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: No plan

Publications

  • Norman DC. Fever in the elderly. Clin Infect Dis. 2000 Jul;31(1):148-51. doi: 10.1086/313896. Epub 2000 Jul 25.

    PubMed 10913413
  • Norman DC, Yoshikawa TT. Fever in the elderly. Infect Dis Clin North Am. 1996 Mar;10(1):93-9. doi: 10.1016/s0891-5520(05)70288-9.

    PubMed 8698997
  • Tal S, Guller V, Gurevich A. Fever of unknown origin in older adults. Clin Geriatr Med. 2007 Aug;23(3):649-68, viii. doi: 10.1016/j.cger.2007.03.004.

    PubMed 17631239
  • Tal S, Guller V, Gurevich A, Levi S. Fever of unknown origin in the elderly. J Intern Med. 2002 Oct;252(4):295-304. doi: 10.1046/j.1365-2796.2002.01042.x.

    PubMed 12366602
  • Norman DC, Wong MB, Yoshikawa TT. Fever of unknown origin in older persons. Infect Dis Clin North Am. 2007 Dec;21(4):937-45, viii. doi: 10.1016/j.idc.2007.09.003.

    PubMed 18061083
  • Vanderschueren S, Del Biondo E, Ruttens D, Van Boxelaer I, Wauters E, Knockaert DD. Inflammation of unknown origin versus fever of unknown origin: two of a kind. Eur J Intern Med. 2009 Jul;20(4):415-8. doi: 10.1016/j.ejim.2009.01.002. Epub 2009 Feb 1.

    PubMed 19524186
  • Knockaert DC, Vanneste LJ, Bobbaers HJ. Fever of unknown origin in elderly patients. J Am Geriatr Soc. 1993 Nov;41(11):1187-92. doi: 10.1111/j.1532-5415.1993.tb07301.x.

    PubMed 8227892
  • Woolery WA, Franco FR. Fever of unknown origin: keys to determining the etiology in older patients. Geriatrics. 2004 Oct;59(10):41-5.

    PubMed 15508555
  • Gafter-Gvili A, Raibman S, Grossman A, Avni T, Paul M, Leibovici L, Tadmor B, Groshar D, Bernstine H. [18F]FDG-PET/CT for the diagnosis of patients with fever of unknown origin. QJM. 2015 Apr;108(4):289-98. doi: 10.1093/qjmed/hcu193. Epub 2014 Sep 9.

    PubMed 25208896
  • Schonau V, Vogel K, Englbrecht M, Wacker J, Schmidt D, Manger B, Kuwert T, Schett G. The value of 18F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study. Ann Rheum Dis. 2018 Jan;77(1):70-77. doi: 10.1136/annrheumdis-2017-211687. Epub 2017 Sep 19.

    PubMed 28928271
  • Mardi D, Fwity B, Lobmann R, Ambrosch A. Mean cell volume of neutrophils and monocytes compared with C-reactive protein, interleukin-6 and white blood cell count for prediction of sepsis and nonsystemic bacterial infections. Int J Lab Hematol. 2010 Aug 1;32(4):410-8. doi: 10.1111/j.1751-553X.2009.01202.x. Epub 2009 Nov 16.

    PubMed 19919621
  • Fusco FM, Pisapia R, Nardiello S, Cicala SD, Gaeta GB, Brancaccio G. Fever of unknown origin (FUO): which are the factors influencing the final diagnosis? A 2005-2015 systematic review. BMC Infect Dis. 2019 Jul 22;19(1):653. doi: 10.1186/s12879-019-4285-8.

    PubMed 31331269

Questions about this trial

What is this clinical trial studying?

An observational study of Fever of Unknown Origin, run by Universitair Ziekenhuis Brussel at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

the spectrum of diseases responsible of FUO or IUO (time frame: through study completion, an average of 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04810351, which also lists 12 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in